Age, median (IQR) (SD) | 63 (51, 70) |
Sex, male n (%) | 38 (63) |
Cancer stage, n (%) | |
Stage III | 9 (15) |
Stage IV | 51 (85) |
Melanoma type, n (%) | |
Cutaneous | 37 (61.7) |
Uveal | 1 (1.7) |
Acral | 1 (1.7) |
Mucosal | 16 (26.7) |
Unknown | 5 (8.3) |
Cycles of ICI received, median (IQR) | 5.5 (3, 18.5) |
Total number of irAE, median (IQR) | 3(2, 5) |
Max irAE grading, n (%) | |
None | 5 (8.3) |
Mild (grade 1–2) | 27 (45) |
Severe (grade 3–5) | 28 (46.7) |
Timing to first irAE, n (%) | |
<6 weeks | 38 (63) |
≥6 weeks | 17 (28) |
Time to first severe irAE, n (%) | |
<6 weeks | 6 (21) |
≥6 weeks | 22 (79) |
ANA positivity, n (%) | |
Baseline | 14 (23.3) |
6 weeks | 14 (23.3) |
Any timepoint | 19 (31.7) |
RF positivity, n (%) | |
Baseline | 4 (6.7) |
6 weeks | 4 (6.7) |
Any timepoint | 6 (10) |
Anti-CCP positivity, n (%) | |
Baseline | 0 |
6 weeks | 1 (2) |
Any timepoint | 1 (2) |
RF, CCP or ANA positive at baseline, n (%) | 17 (28) |
RF, CCP or ANA positive at any timepoint, n (%) | 24 (40) |
ANA, antinuclear antibody; anti-CCP, anti-cyclic citrullinated peptide; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; RF, rheumatoid factor.